Alameda, CA - May 8, 2007 Advanced Cell Technology (OTCBB: ACTC), a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine, will be presenting at Rodman & Renshaw's 4th Annual Global Healthcare Conference in Monte Carlo, Monaco on Monday, May 14th at 5:00 PM local time (11:00 AM EST).
William M. Caldwell, IV, Chairman and CEO, will be providing an update on the Company's developments and business strategy. Further, Mr. Caldwell will be highlighting the company's recent groundbreaking discovery that shows precursor cells, generated from human embryonic stem cells, have the ability to repair vascular damage in animals.
"The ability to repair vascular damage using these cells could have a profound impact on a large number of diseases that are major human afflictions,” said Robert Lanza, M.D., Vice President of Research & Scientific Development at ACT, and senior author of the study. "Our results suggest the possibility of using nature's early cellular developmental components to restore vascularization and function in patients with vascular disease. An injection of these cells may be able to prevent a patient from having a leg amputated or from dying after a heart attack.”
The Conference will include presentations by over 200 companies, as well as experts from the medical, scientific and investment communities. Mr. Caldwell will be available to meet one-on-one with investors throughout the Conference.
A copy of the presentation can be downloaded in PDF format by visiting the "Conference Presentations page":/conference-presentations/ of our website.
A live audio web cast of this presentation can be accessed by clicking here.
Further, you can access additional information about Advanced Cell and an audio replay of the presentation on this site for 90 days after the conference.
About Rodman & Renshaw
Rodman & Renshaw, LLC is a privately held, full-service investment bank committed to fostering the long-term success of emerging growth companies through capital raising, strategic advice, insightful research, and the development of institutional support.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
For more information, please visit: "www.advancedcell.com":http://www.advancedcell.com.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the annual report on Form 10-KSB for the fiscal year ending December 31, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
The Investor Relations Group
Joseph Kessler or James Carbonara
The Investor Relations Group